Brian Daniels

Brian Daniels, MD joined 5AM ventures in 2018. Prior to his joining, Brian spent two plus decades in clinical drug development in the industry; the last 10 years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He directed the development of numerous innovative medicines that have contributed to the improvement in health for patients across a range of serious diseases. These include: ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ELIQUIS in thrombosis/atrial fibrillation, ONGLYZA and FARXIGA in diabetes, ABILIFY in depression, MYOLEPT in rare diseases, SPRYCEL, OPDIVO, ERBITUX, YERVOY and IXEMPRA in oncology. Brian received a BS and MS from MIT and his MD from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF.